Cryoport, Inc. (CYRX)
| Market Cap | 477.66M |
| Revenue (ttm) | 243.80M |
| Net Income (ttm) | 63.27M |
| Shares Out | 50.07M |
| EPS (ttm) | 1.27 |
| PE Ratio | 7.54 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 494,947 |
| Open | 9.90 |
| Previous Close | 9.88 |
| Day's Range | 9.36 - 9.90 |
| 52-Week Range | 4.58 - 11.44 |
| Beta | 1.52 |
| Analysts | Strong Buy |
| Price Target | 12.83 (+34.49%) |
| Earnings Date | Nov 4, 2025 |
About CYRX
Cryoport, Inc. provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and reproductive medicine markets worldwide. The company’s Life Sciences Services segment provides temperature-controlled logistics and cryogenic biostorage within the life science industry. Its Life Sciences Products segment offers cryogenic freezers, cryogenic dewars, and accessories within the life science industry through direct sales or a distribution network. The company’s products include Cryoport Express Shippers; Cryoport ELITE Shi... [Read more]
Financial Performance
In 2024, Cryoport's revenue was $228.39 million, a decrease of -2.09% compared to the previous year's $233.26 million. Losses were -$122.76 million, 14.1% more than in 2023.
Financial StatementsAnalyst Forecast
According to 9 analysts, the average rating for CYRX stock is "Strong Buy." The 12-month stock price target is $12.83, which is an increase of 34.49% from the latest price.
News
Cryoport: Picks And Shovels For The Gene Therapy Boom
Cryoport, Inc. (CYRX) is the leading provider of temperature-controlled supply chain solutions for the rapidly growing cell and gene therapy industry. CYRX supports 745 clinical trials and 19 commerci...
Cryoport Systems Wins 2025 BioTech Breakthrough Award For “BioServices Innovation of the Year”
Annual Awards Program Recognizes Breakthrough Life Sciences & Biotechnology Innovation Around the World Annual Awards Program Recognizes Breakthrough Life Sciences & Biotechnology Innovation Around th...
Cryoport, Inc. (CYRX) Q3 2025 Earnings Call Transcript
Cryoport, Inc. ( CYRX) Q3 2025 Earnings Call November 4, 2025 5:00 PM EST Company Participants Jerrell Shelton - Chairman, President & CEO Robert Stefanovich - Senior VP, CFO, Treasurer & Chief Admin...
Cryoport Reports Strong Q3 Results, Raises FY25 Outlook
Cryoport Inc (NASDAQ:CYRX) reported third-quarter financial results after the market close on Tuesday. Here's a rundown of the temperature-controlled supply chain solutions company's report.
Cryoport Reports Third Quarter 2025 Financial Results
Third quarter revenue increased 15% year-over-year to $44.2 million Commercial Cell & Gene Therapy revenue increased 36% year-over-year to $8.3 million Life Sciences Services revenue grew 16% year-ove...
Cryoport Continues to Set New Benchmarks for the Global Regenerative Medicine Supply Chain
First Global Supply Chain Solutions Company to Achieve ISO 21973 Certification, Ensuring Highest Transport Safety, Traceability, and Integrity Standards for Cell and Gene Therapies NASHVILLE, Tenn. , ...
Cryoport to Report Third Quarter 2025 Financial Results on November 4, 2025
NASHVILLE, Tenn. , Oct. 21, 2025 /PRNewswire/ -- Cryoport, Inc. (Nasdaq: CYRX) ("Cryoport" or the "Company"), a global leader in temperature-controlled supply chain solutions for the life sciences, to...
MVE Biological Solutions, A Cryoport Company, Introduces Real-Time Integrated Condition Monitoring Systems For Cryogenic Dewars
Connected, Intelligent Condition Monitoring Assets that Safeguard Vital Life Science Materials Mark MVE's First Step in its Real-Time Integrated Systems Evolution NASHVILLE, Tenn. , Oct. 7, 2025 /PRNe...
Cryoport Systems Expands Global Footprint with New Global Supply Chain Center in Paris, France
The 55,000-Square-Foot Facility is the Latest Addition to Cryoport Systems' Global Supply Chain Center Network Designed to Support Complex Life Sciences Supply Chain Needs, Including Biologistics, Bio...
Cryoport (CYRX) Q2 Revenue Jumps 14%
Cryoport (CYRX) Q2 Revenue Jumps 14%
Cryoport, Inc. (CYRX) Q2 2025 Earnings Call Transcript
Cryoport, Inc. (NASDAQ:CYRX) Q2 2025 Earnings Conference Call August 5, 2025 5:00 PM ET Company Participants Jerrell W. Shelton - Chairman, President & CEO Mark W.
Cryoport Reports Second Quarter 2025 Financial Results
Second quarter revenue increased 14% year-over-year to $45.5 million Commercial Cell & Gene Therapy revenue increased 33% year-over-year to $8.7 million Life Sciences Services revenue rose 21% year-ov...
Cryoport to Report Second Quarter 2025 Financial Results on August 5, 2025
NASHVILLE, Tenn. , July 22, 2025 /PRNewswire/ -- Cryoport, Inc. (Nasdaq: CYRX) ("Cryoport" or the "Company"), a global leader in temperature-controlled supply chain solutions for the life sciences, to...
Cryoport's MVE Biological Solutions Introduces Next Generation Vapor Shippers
New SC vapor shipper series improves reliability through extended hold times and patented impact-absorbing and Vapor Shield Technology NASHVILLE, Tenn. , July 8, 2025 /PRNewswire/ -- Cryoport, Inc. (N...
CEO Jerrell Shelton Sells Some Shares of Cryoport (CYRX)
According to the SEC Form 4 filing on June 26, 2025, Jerrell Shelton, president and CEO, exercised $5 per share options on 16,344 shares of Cryoport (CYRX 0.68%) and proceeded to sell them at $7.0586 ...
Cryoport Completes CRYOPDP Divestiture and Commences Strategic Partnership with DHL Group
NASHVILLE, Tenn. , June 12, 2025 /PRNewswire/ -- Cryoport, Inc. (Nasdaq: CYRX) ("Cryoport" or the "Company"), a leader in temperature-controlled supply chain solutions for the Life Sciences, with a fo...
Cryoport, Inc. (CYRX) Q1 2025 Earnings Call Transcript
Cryoport, Inc. (NASDAQ:CYRX) Q1 2025 Results Conference Call May 7, 2025 5:00 PM ET Company Participants Jerrell Shelton - CEO Robert Stefanovich - CFO Mark Sawicki - Chief Scientific Officer Thomas ...
Cryoport Reports First Quarter 2025 Financial Results
Commercial Cell & Gene therapy revenue of $7.2 million, up 33% year over year Q1 2025 revenue from continuing operations of $41.0 million, up 10% year over year Supporting 711 global clinical trials a...
Cryoport to Report First Quarter 2025 Financial Results on May 7, 2025
NASHVILLE, Tenn. , April 24, 2025 /PRNewswire/ -- Cryoport, Inc. (Nasdaq: CYRX) ("Cryoport" or the "Company"), a global provider of supply chain solutions for the life sciences sector, today announced...
Cryoport, Inc. (CYRX) Strategic Agreement and Transaction with DHL Group Call (Transcript)
Cryoport, Inc. (NASDAQ:CYRX) Strategic Agreement and Transaction with DHL Group Call March 31, 2025 8:30 AM ET Company Participants Todd Fromer - Investor Relations, KCSA Strategic Communications Jer...
DHL Group acquires CRYOPDP from Cryoport to strengthen "DHL Health Logistics"
DHL to acquire 100% of CRYOPDP, a leading specialty courier providing logistics services for clinical trials, biopharma, and cell & gene therapies. This acquisition enhances DHL's capabilities in spec...
Cryoport to Host Investor Call to Discuss Recent Strategic Agreement and Transformative Transaction Today, March 31, 2025, at 8:30 a.m. ET
NASHVILLE, Tenn. , March 31, 2025 /PRNewswire/ -- Cryoport, Inc. (Nasdaq: CYRX) ("Cryoport" or the "Company"), a global leader in supply chain solutions for the life sciences sector, today announced t...
Cryoport's MVE Biological Solutions Expands High-Efficiency Cryogenic Freezer Series With Answer to Evolving Needs of Fertility Clinics, Biorepositories and Clinical Laboratories
NASHVILLE, Tenn. , March 12, 2025 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or "the Company"), a global leader in supply chain solutions for the life sciences, today announced the laun...
Cryoport, Inc. (CYRX) Q4 2024 Earnings Call Transcript
Start Time: 17:00 January 1, 0000 5:41 PM ET Cryoport, Inc. (NASDAQ:CYRX) Q4 2024 Earnings Conference Call March 04, 2025, 17:00 PM ET Company Participants Jerrell Shelton - CEO Robert Stefanovich - ...
Cryoport Reports Fourth Quarter and Full Year 2024 Financial Results
FY 2024 revenue of $228.4 million, in-line with company guidance Commercial Cell & Gene Therapy revenue rose to $26 million in FY 2024, up 20% year-over-year Supporting a record total of 701 global cl...